The company is launching a pilot program to accelerate Medicare Advantage payments to rural hospitals, aiming to cut payment cycles by 50% to under 15 days to ease cash flow. However, it faces a Senate committee investigation into aggressive tactics to boost Medicare payments. The stock trades at a reduced valuation after poor performance, and analysts are debating its 2026 outlook, noting both significant problems to fix and a potential bull case. The company expects over $50 billion in specialty revenue for fiscal 2026.